Pfizer
Search results
Seagen is now part of Pfizer and develops transformative therapies for solid tumors and blood-related cancers. Learn more about their mission, science, and how they help patients and their families.
- Patient or Caregiver
At Seagen, we are passionate about helping people living...
- Our Medicines
Report an adverse event or request additional information...
- Featured Content
Learn how Seagen is revolutionizing cancer care through our...
- Your Privacy Choices
Seagen is now part of Pfizer! Please visit Pfizer.com for...
- FAQs
From the year 2013 to 2020, Seagen is required to report...
- Science and Research
Seagen is developing a new generation of targeted, empowered...
- Join Our Team
At Seagen, all kinds of people—researchers, advocates,...
- Tisotumab Vedotin
Tisotumab vedotin. Explore Ongoing Studies See How It Works....
- Patient or Caregiver
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Dec 14, 2023 · Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “Cancer remains a leading cause of death, and one in three people in the U.S. will receive a cancer diagnosis in their lifetime.
Pfizer and Seagen are reimagining the future of cancer with a portfolio of innovative medicines. Explore the products, prescribing information, and news from the two companies.
Mar 13, 2023 · About Seagen. Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.
Dec 14, 2023 · Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “ Cancer remains a leading cause...
Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. Learn about its pipeline of investigational compounds or uses of marketed products for various hematologic and solid tumors.
